Medicaid Services Investment and Accountability Act of 2019
Public Law 116-16 · H.R. 1839 · 116th Congress · began in the House
Signed by Donald Trump (R) on Apr 18, 2019 · Health
Sponsor: Rep. Raul Ruiz (D-CA-36)
Cosponsors (8): Rep. Kurt Schrader, Rep. Markwayne Mullin,
Passage votes
- HouseVoice vote
- SenateVoice vote
Data notes
The final version of the law, as each chamber passed it. A chamber that passed it by voice vote or unanimous consent has no count. “Method not stated” means the record does not say how the chamber voted. Where the record has a member-by-member vote, the “Who voted for it” section shows who voted yea.
Summary
The Congressional Research Service’s plain-language summary of what the law does.
Medicaid Services Investment and Accountability Act of 2019
This bill alters several Medicaid programs and funding provisions.
(Sec. 2) The bill temporarily extends the applicability of Medicaid eligibility criteria that protect against spousal impoverishment for recipients of home- and community-based services.
(Sec. 3) The bill also establishes a state Medicaid option to provide for medical assistance with respect to coordinated care provided through a health home (i.e., a designated provider or team of health-care professionals) for children with medically complex conditions. States must determine payment methodologies in accordance with specified requirements; payments also temporarily qualify for an enhanced federal matching rate.
(Sec. 4) The bill also temporarily extends the Medicaid demonstration program for certified community behavioral health clinics.
(Sec. 5) The bill increases funding available to the Money Follows the Person Rebalancing Demonstration Program. (Under this program, the Centers for Medicare & Medicaid Services may award grants to state Medicaid programs to assist states in increasing the use of home and community care for long-term care and decreasing the use of institutional care.)
(Sec. 6) Further, drug manufacturers with Medicaid rebate agreements for covered outpatient drugs must disclose drug product information. Manufacturers are subject to civil penalties for knowingly misclassifying drugs. Manufacturers are also required to compensate for rebates that were initially underpaid as a result of misclassification (whether or not such misclassification was committed knowingly).
Committees
The committees the bill was sent to, and what each did with it.
Data notes
A committee links to its page only where it exists in the current Congress; older and renamed committees are named without a link.
Related bills
4 bills the Library of Congress relates to this one.
H.R. 937Related bill
Right Rebate Act of 2019
H.R. 1226Related bill
ACE Kids Act of 2019
S. 205Related bill
Right Rebate Act of 2019
S. 317Related bill
ACE Kids Act of 2019
Data notes
Related bills are identified by the Congressional Research Service, the House and the Senate: companion and identical bills, bills with similar text, bills that were folded into this law, and rules that brought it to the floor. A bill that is itself a public law in this site’s data links here; the others link to Congress.gov.
Timeline
From introduction to signing, newest first: the committees, the floor and the president. 17 actions.
- Apr 18, 2019Became lawBecame law · Became Public Law No: 116-16.
- Became lawBecame law · Signed by President.
- Apr 10, 2019FloorFloor · Presented to President.
- CommitteeCommittee · Sponsor introductory remarks on measure. (CR H3224)
- Apr 3, 2019FloorFloor · Message on Senate action sent to the House.
- Apr 2, 2019FloorFloor · Passed Senate without amendment by Voice Vote.
- Mar 26, 2019CommitteeCommittee · Received in the Senate, read twice.
- Mar 25, 2019FloorFloor · Motion to reconsider laid on the table Agreed to without objection.
- FloorFloor · On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
- FloorFloor · Considered as unfinished business.
- FloorFloor · At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Burgess objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
- FloorFloor · DEBATE - The House proceeded with forty minutes of debate on H.R. 1839.
- FloorFloor · Considered under suspension of the rules.
- FloorFloor · Mr. Ruiz moved to suspend the rules and pass the bill, as amended.
- Mar 22, 2019CommitteeCommittee · Referred to the Subcommittee on Health.
- Mar 21, 2019CommitteeCommittee · Referred to the House Committee on Energy and Commerce.
- IntroducedIntroduced · Introduced in House
Data notes
Every action the Library of Congress lists for the bill, from introduction to signing, plus the dated committee hearings. The source lists many steps twice (the chamber’s own entry and the Library of Congress copy, or a presidential and a became-law entry with the same words); those are shown once. Amendments are listed in their own section.
Amendments
No amendments to this bill are on record.
Data notes
Amendments offered to this bill in either chamber, as the Library of Congress records them: each with a status read from its last recorded step: agreed to, rejected, withdrawn, ruled out of order, fell with another amendment, or offered with no vote recorded (most Senate amendments are only ever offered). The wording of each amendment is the source’s. Amendments to amendments and amendments to other bills are not listed.
Official record
The bill’s full text is on Congress.gov. Data through Oct 7, 2026.